EVALUATION OF A MODIFIED BIOMATERIAL OF TYMPANOTONUS FUSCATA SHELL POWDER I: FORMULATION OF THEOPHYLLINE HYDRATE AND HYDROCHLOROTHIAZIDE TABLETS.
A modified biomaterial of periwinkle shell powder, MBPSP derivative of Tympanotonus fuscata shell was applied as a diluent in theophylline hydrate (TPH) and hydrochlorothiazide (HCTZ) tablets. A 100 g of the pulverized periwinkle shell was digested with 166.0 ml of 2 M hydrochloric acid, filtered and neutralized with 5 M sodium hydroxide. Ortho-phosphoric acid was added drop wise until a thick, dehydrated mass was obtained. It was dried at 60 o C and milled to 250 Î¼m size and designated as MBPSP. Using this, batches of granules containing TPH (100 mg) and HCTZ (50 mg) were produced by the wet granulation technique alongside lactose and dicalcium phosphate dihydrate (DCP). They were tableted at 7.55kN using a 10.50 mm diameter die and flat-faced punch on a hydraulic hand press. Tablet properties were evaluated. The weight variation for the TPH or HCTZ tablets produced from MBPSP, lactose or DCP were between 0.03- 0.32 %. The total drug content for the respective batches of tablets was within 85-118 % of the claimed label potency. Though the respective batches of tablets of TPH and HCTZ containing MBPSP, lactose or DCP maintained significantly high values of mechanical strength, the tablets of TPH and HCTZ prepared with DCP generally showed significantly higher values of mechanical strength than those of MBPSP and lactose. Dissolution profile showed that at 45.00 min, 73.13, 87.72 and 87.45 % of TPH was released from the tablets containing lactose, MBPSP and DCP respectively while at 60.00 min, 64.58, 57.84 and 66.00 % of HCTZ was dissolved from the tablets having lactose, MBPSP and DCP respectively. Though MBPSP compared significantly favourably with lactose and DCP in the various tablet parameters evaluated, the tablets of TPH or HCTZ comprising MBPSP displayed very significant shorter tablet disintegration time and also maintained a significantly greater mechanical strength in comparison to lactose and DCP. Therefore, MBPSP could be a very useful excipient in the formulation of TPH and HCTZ immediate-release tablets.
Keywords: Modified biomaterial, Tympanotonus fuscata, periwinkle, shell, theophylline hydrate, hydrochlorothiazide, tablet.
2. Augsburger LL, Hoag SW (eds). Pharmaceutical Dosage Forms. In: Tablets (3rd edition), Volume 2: Rational Design and Formulation. New York, Informa Healthcare, 2008.
3. Gupta P, Nachaegari SK, Bansal AK. Improved excipient functionality by coprocessing. In: Katdare A, Chaubal MV CO Eds. Excipient Development for Pharmaceutical, Biotechnology and Drug Delivery systems. New York, Informa Healthcare, 2006. Pp. 109-126.
4. Moreton RC. Excipient functionality, Pharm Technol, 2004; 28: 98, 99,119.
5. Tousey MD. The manufacturing process: tablet and capsule manufacturing. Solid dose Experts Techceuticals Training. 2015; (15):1-12.
6. Ugoeze K.C, Chukwu A. Preliminary Evaluation of the Properties of Biomaterial of Tympanotonus fuscata shell as Pharmaceutical Excipient. Int. Res. J. Pharm. 2015; 6(2):104-107.
7. Ugoeze K.C, Chukwu A. Physico-chemical Properties of a Modified Biomaterial from Tympanotonus Fuscata (Periwinkle) Shell Powder Considered as Pharmaceutical Excipient. Journal of Pharmaceutical and Allied Sciences, 2017; 14 (1):2417-2429.
8. Ugoeze K. C., Udeala O. K. Application of Periwinkle Shell Bio-ash (Ugoeze-bio-ash) as CO2 Donor in the Formulation of an Effervescent Low Dose Aspirin Tablet. American Journal of Biomedical Science and Engineering, 2015; 1(5):63-70.
9. British Pharmacopeia, 1998; Her Majestyâ€™s Stationery Office, London.
10. Shangraw, R.F. Direct Compression Tabletting, Encyclopaedia of Pharmaceutical Technology, Vol.4, Marcel Dekker, U.S.A., 2nd ed., 1988; pp. 85-160.
11. Shangraw, R.F. Compressed tablets by direct compression granulation in: Pharmaceutical Dosage Forms: Tablets, Vol.1, Marcel Dekker, U.S.A., 2nd ed., 1989; p. 195-246.
12. Setn, B.B; Bandelin, F.J. and Shangraw, R.F. Tablets in: Pharmaceutical Dosage Forms, Vol. I; Liebermann, H. and Lachman, L. (eds.), Marcel Dekker Inc, New York, 1980; p.110.
13. Marks, A.M. & Sciarra, J.J. Effects of size and other physical properties of granules and their corresponding tablets, J. Pharm. Sci. 1968; 57:497.
14. Parrot, E.L. Pharmaceutical Technology; Fundamental Pharmaceutics, Burges Pub. Co., Minneapolis, 1970; pp. 17-18, 74.
15. Lazarus, J. and Lachman, L. Experiences in development of directly compressible tablets containing potassium chloride, J. Pharm. Sci. 1966; 55: 1121.
16. Rasenack, N. and Muller, B.W. Crystal habit and tableting behaviour, Int. J. Pharm. 2002; 244:45-57.
17. Sherringtonn, P.J.; Oliver, R. Granulation: in: Encyclopaedia of Pharmaceutical Technology, Vol. 3, 2nd Edition, Edited by James Swarbrick and James C. Boylan, Marcel Dekker, Inc. New York, 1981; pp. 2713-2731.
18. Ejiofor, O; Esezobo, S, Pilpel, N. The plasto-elasticity and compressibility of coated powders and the tensile strength of their tablets, J. Pharm. Pharmac. 1986; 38 (1):1-7.
19. The United States Pharmacopoeia, U.S.P, NF. The United States Pharmacopoeial Convention, Rockville, 2007.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).